Why this page exists. CIRS is brutal and the Shoemaker Protocol is demanding. People in the middle of treatment routinely look for evidence that improvement is documented — not as encouragement copy, but as published research they can read and verify.
Below are seven peer-reviewed papers from Dr. Ritchie Shoemaker's research and the broader CIRS literature. Each entry includes the full citation, the relevant finding, and links to verify the paper independently. Citations link to Surviving Mold's research index (which hosts most of these papers as PDFs) and a Google Scholar search by title.
None of this is medical advice. None of it predicts an individual outcome. It is what the published research documents.
Brain volume and biomarker improvement with VIP therapy
Finding: Intranasal VIP treatment (>12 weeks, >6 doses/day) safely corrected multinuclear grey matter atrophy in CIRS patients, while also reducing MMP-9, TGF‑β1, and C4a, raising VEGF, and normalizing clotting abnormalities.
Finding: HIF 1A pathway overexpression in CIRS patients drives proliferative physiology and pulmonary artery hypertension; VIP therapy reduces HIF 1A by resolving aberrant mitochondrial transcriptomics.
Reversibility of fatigue and cellular metabolism
Finding: CIRS patients show suppression of ribosomal and mitochondrial gene expression (molecular hypometabolism) that reverses during treatment, with VIP therapy correcting overshoot via insulin signaling mechanisms.
Documented clinical efficacy of the Shoemaker Protocol
Finding: Literature review of 13 CIRS treatment articles found the Shoemaker Protocol to be the only treatment with documented clinical efficacy for CIRS, with efficacy demonstrated in 11 of 13 articles reviewed.
Grey matter atrophy improvement and coagulation
Finding: Correction of prothrombotic coagulation gene overexpression via GENIE-guided treatment accompanies clinical improvement in grey matter nuclear atrophy and early-onset dementia associated with water-damaged building exposure.
Foundational symptom-resolution data
Finding: First clinical case series documenting Pfiesteria-related illness treated with cholestyramine (CSM), showing symptom resolution within 2 weeks and normalized neurocognitive scores at 3-month follow-up. The foundational paper that established cholestyramine as an effective treatment for biotoxin-mediated illness.
Twenty-five-year retrospective
Finding: A 25-year retrospective describing the evolution from identifying water-damaged-building illness through the biotoxin paradigm, biomarker development, and transcriptomics. Documents the sequential framework that has been applied across 14,000+ research-tracked patients.
What this is. A reference list of peer-reviewed research documenting biomarker, brain-volume, and clinical improvement in CIRS patients following the Shoemaker Protocol. Citations are summarized; the full text of each paper lives at the linked sources.
What this isn't. Medical advice. A promise of an individual outcome. A substitute for working with a qualified provider. Bodies don't all heal on the same timeline; some people in the published cohorts saw faster improvement than others, and some require longer treatment. Always work with a clinician who knows your case.
Got a paper to add? Email editorial@themoldreport.com. We update this list when material new research is published.